#USA #Aliso Viejo #Terumo Neuro #WEB Device #Aneurysm Treatment

Terumo Neuro Celebrates 15 Years of the WEB™ Device

In March 2025, Terumo Neuro, a premier name in neurovascular innovations, proudly celebrated the 15th anniversary of its revolutionary Aneurysm Embolization System, known as the WEB™ device. Launched in October 2010 after receiving the CE mark in Europe, this pioneering device has fundamentally changed the approach to treating wide-neck bifurcation aneurysms, providing a clinically validated solution with remarkable ease of use, safety, and durability.

The introduction of the WEB device marked a watershed moment in aneurysm treatment. More than 25,000 units have been implanted globally, significantly altering clinical practices. The first implantation was performed by Professor Joachim Klisch in Germany, heralding a new era in aneurysm care. In the years since, the device has proven its effectiveness through numerous studies, establishing itself as a safe and efficacious alternative to traditional treatment methods like coils and stents.

CEO Carsten Schroeder remarked on the milestone, stating, "The WEB device has set a new standard in aneurysm management and has been integral to our mission of improving neurovascular care. With 15 years of proven clinical success, WEB continues to enhance patient outcomes while reducing the need for multiple devices and lengthy procedures. We celebrate this achievement and remain committed to innovating alongside leading physicians worldwide."

Transformative Features of the WEB™ Device

The WEB device is lauded for being the world’s first intra-saccular flow disruptor designed specifically for treating intracranial aneurysms from inside the aneurysmal sac. Unlike conventional treatments, which typically require dual anti-platelet therapy, this device reduces the risks associated with extensive medication protocols while simplifying procedures and improving patient safety.

Clinical Data and Safety Profile

Backed by extensive clinical data, the WEB device's efficacy is supported by seven Good Clinical Practice (GCP) studies involving over 600 patients. Notably, there have been zero rebleeding incidents reported during more than 1,464 patient-years following treatment with the WEB device. Follow-up studies have confirmed an exceptional degree of long-term safety, encompassing zero device-related morbidity or mortality over five-year monitoring periods.

Enhancements and Expanded Treatment Options

The introduction of the WEB 17 system—featuring a lower profile—has further refined aneurysm treatment protocols, offering clinicians greater flexibility and precision across a wider variety of cases. This ongoing evolution of the WEB device highlights Terumo Neuro's unwavering commitment to advancing neurovascular technology.

As the WEB device remains the preferred choice of countless practitioners tasked with managing wide-neck bifurcation aneurysms using a single device, it continues to evolve, meeting the dynamic needs of the healthcare landscape.

About Terumo Neuro

Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro aims to deliver game-changing innovations that redefine the possibilities within neuroendovascular care. The company’s portfolio includes over thirty products designed for treating cerebral aneurysms, ischemic strokes, carotid artery diseases, and vascular malformations. Headquartered in Aliso Viejo, California, Terumo Neuro operates in over seventy countries, ensuring that their cutting-edge technologies are accessible to medical professionals and patients alike.

About Terumo Corporation

Terumo Corporation (TSE4543) is a leading global medical technology company dedicated to providing healthcare solutions for over a century. Headquartered in Tokyo, Japan, and employing more than 30,000 professionals worldwide, Terumo strives to deliver innovative medical solutions across more than 160 countries. From its origins as a thermometer manufacturer, Terumo's expansive business now spans vascular and cardiac surgical interventions, blood transfusion technologies, and essential medical products for everyday clinical practice. Dedication to improving patient outcomes remains central to Terumo's ethos, ensuring they continue to serve healthcare professionals and society effectively.

To learn more about Terumo Neuro and its products, visit www.terumoneuro.com.